Go to deals
Private Equity | Healthcare

Gilde Healthcare has invested in Tandarts Today

April 2021 — Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.

Tandarts Today, founded in 2015, offers all disciplines of regular dentistry, including special treatments such as implantology, orthodontics, periodontology and aesthetic treatments. Furthermore, through its own dental laboratories, it develops hockey bits, custom-made prostheses, bridges and other dental work pieces.

Gilde Healthcare is a specialized European healthcare investor managing over US$1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies, with a focus on the Benelux and DACH regions. The private equity fund targets healthcare, suppliers of medical products and service providers in the healthcare market.

Our role in the transaction

Oaklins’ team in the Netherlands acted as the exclusive financial advisor to the seller in this transaction.

Parties
“I am delighted to welcome Gilde Healthcare as a shareholder in Tandarts Today. Their experience in buy-and-build strategies combined with their healthcare angle and focus makes Gilde Healthcare the perfect partner to realize Tandarts Today’s growth objectives. Oaklins played a fundamental role in identifying Gilde Healthcare as a buyer and realizing the transaction in a dedicated and professional manner.”

Ruben Hoefnagels

Founder and CEO, Tandarts Today

Talk to the deal team

Adse de Kock

Partner
Amsterdam, Netherlands
Oaklins Netherlands

Sander van 't Spijker

Associate Director
Amsterdam, Netherlands
Oaklins Netherlands

Related deals

Cibus has acquired Aweta from Standard Investment
Private Equity | Agriculture | Industrial Machinery & Components

Cibus has acquired Aweta from Standard Investment

Standard Investment has reached an agreement with Cibus Capital, advisor to the Cibus funds, on the sale of Aweta, a global leader in fruit and vegetable sorting, grading and packing equipment. Completion of the transaction is expected in the coming weeks. The transaction provides Aweta with a strong partner to support the company’s next growth phase. Under Cibus’ ownership, Aweta will pursue further international growth and accelerate investment in R&D, supporting the installed base and product innovation, including software and AI capabilities. Aweta’s leadership team will continue to lead the business.

Learn more
Comtax has been acquired by Ryan
Private Equity | Business Support Services | TMT

Comtax has been acquired by Ryan

Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.

Learn more
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Healthcare

Katalyst Diagnostics has been acquired by Cruinn Diagnostics

Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.

Learn more